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The transcription factor PU.1 is critical for multiple hematopoietic lineages, but different leukocyte types
require strictly distinct patterns of PU.1 regulation. PU.1 is required early for T-cell lineage development but
then must be repressed by a stage-specific mechanism correlated with commitment. Other lineages require
steady, low expression or upregulation. Until now, only the promoter plus a distal upstream regulatory element
(URE) could be invoked to explain nearly all Sfpi1 (PU.1) activation and repression, including bifunctional
effects of Runx1. However, the URE is dispensable for most Sfpi1 downregulation in early T cells, and we show
that it retains enhancer activity in immature T-lineage cells even where endogenous Sfpi1 is repressed. We now
present evidence for another complex of conserved noncoding elements that mediate discrete, cell-type-specific
regulatory features of Sfpi1, including a myeloid cell-specific activating element and a separate, pro-T-cell-
specific silencer element. These elements yield opposite, cell-type-specific responses to Runx1. T-cell-specific
repression requires Runx1 acting through multiple nonconsensus sites in the silencer core. These newly
characterized sites recruit Runx1 binding in early T cells in vivo and define a functionally specific scaffold for
dose-dependent, Runx-mediated repression.
The Ets family transcription factor PU.1 provides essential
pleiotropic inputs regulating multiple cell fate decisions during
differentiation of blood cells from hematopoietic stem cells
(HSCs). Its roles all depend on tight regulation of PU.1 itself,
with different levels and patterns of expression distinguishing
various cell lineages and different developmental phases. PU.1
is essential for the development of myeloid and lymphoid lin-
eages (22, 30), but inappropriately controlled expression can
cause severe developmental defects and/or malignancy. The
precise basis of PU.1 regulation is therefore important to re-
solve and could be a model for multifunctional transcription
factor deployment in development from stem cells.
PU.1 is expressed specifically in HSCs and their derivatives.
Upon differentiation of HSCs, PU.1 expression is silenced in
erythroid cells but elevated in macrophages, continues at mod-
erately high levels in neutrophils and most types of dendritic
cells, and is fixed at lower levels in committed B cells (4, 24). A
particularly dramatic shift of PU.1 expression occurs in the
development of T cells. Although the earliest intrathymic pre-
cursors express PU.1 at HSC-like levels, PU.1 expression is
silenced during the transition to the DN3 stage of T-cell de-
velopment, as the cells undergo lineage commitment (3, 33,
35). This silencing is crucial, as forced expression of PU.1
beyond this stage causes a developmental block. PU.1 overex-
pression in DN3 thymocytes or a DN3-like immature T-cell
line, Adh.2C2, can also cause the cells to gain myeloid char-
acteristics (2, 10, 19), linking the silencing of PU.1 to exclusion
of alternative fate choices during T-lineage commitment. The
mechanism of this essential silencing event is not fully under-
stood.
To date, most aspects of PU.1 regulation have been ex-
plained by invoking just two regulatory elements: the promoter
and an upstream regulatory element (URE) at 14 kb up-
stream of the transcription start site of the Sfpi1 gene, which
encodes PU.1. Both are suggested to contribute to cell type
specificity (20). Thus, differential regulation would imply roles
for different combinations of transcription factors working at
these same elements. The Sfpi1 promoter contains octamer
binding sites affecting B-cell expression (7), while PU.1 can
bind its own promoter with Sp1 to regulate itself in myeloid
cells (8). Sfpi1 promoter activity can also be directed in my-
eloid cells by C/EBP and AP-1 (5). These regulatory inputs to
Sfpi1 may be modulated by cell-type-specific DNA methylation
as well (1). The promoter alone cannot drive reporter expres-
sion in a chromatin context, however, and the search for added
regulatory function yielded the conserved URE (around kb
14), reported to be a myeloid-specific enhancer, enhancing
promoter activity in a myeloid cell line but not in a mature
T-cell line (20). In myeloid cells, the URE binds C/EBP (6,
38) and PU.1 and may thus contribute to autoregulation as well
(26, 31).
Data suggest that the URE could also play a role in silencing
in T cells, and two mechanisms have been offered for this.
First, a TCF/LEF site in the distal URE could promote repres-
sion as long as Wnt signals are absent (28). However, this
mechanism does not explain continued PU.1 repression at
stages of development when T cells are known to require
canonical Wnt signaling (12, 37). Second, a Runx input into the
URE was proposed to mediate silencing as well as activation
(17). Initiation of PU.1 expression in HSCs depends on Runx1,
which unfolds the chromatin structure of the Sfpi1 gene and
primes it for expression (16, 25). The proximal URE enhancer
has three conserved Runx1 sites able to bind Runx1. Mice with
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a deletion either of Runx1 itself or of these URE Runx sites
showed a decrease in PU.1 expression in myeloid and B cells.
In T-lineage cells, deletion of Runx1 produces a developmen-
tal block at the DN2 stage (13, 18), and the surviving cells have
higher PU.1 expression, consistent with Runx1 repression of
Sfpi1 (17). However, URE Runx sites are maintained in an
open state of accessibility, with the Runx sites apparently oc-
cupied, in PU.1-expressing myeloid and B cells and PU.1-
negative T-lineage cells alike (15). Thus, it remains unresolved
how both the initial activation and the T-lineage-specific si-
lencing of Sfpi1 can be mediated by the same factor binding to
the same sites.
However, it is not proven that all regulation of Sfpi1, even by
Runx1, goes through the URE. Deletion of the URE (URE)
neither fully blocked activation of PU.1 expression within he-
matopoietic cells nor fully blocked T-cell silencing (28, 29).
Thus, while required for normal regulatory output, the URE
was dispensable for turning on PU.1 (29). Also, the URE
mice still had T cells in which PU.1 expression was effectively
silenced (28). Even though the Runx1 bound to the URE in T
cells might be part of a repressive complex, lack of the URE
had a milder effect on T-cell development than the severe DN2
developmental block observed with deletion of Runx1 itself.
Thus, Runx factors might act in part through elements beyond
the URE.
Here, we have identified a set of conserved, previously un-
defined cis-regulatory regions for Sfpi1. One is a novel en-
hancer that can amplify myeloid cell-specific expression of
PU.1. Another new element is a bipartite silencer that is nec-
essary and sufficient for full silencing within a chromatin con-
text in an immature, DN3-like T-cell line. We show that in this
immature T-cell line, unlike a mature T-cell line, the URE
remains active as an enhancer, although endogenous PU.1 is
fully repressed; the new repression element enables neutral-
ization of URE enhancer activity. Mapping the sites required
for the core silencer function revealed them to be novel Runx
binding sites. These Sfpi1 silencer sites bind Runx1 in a dose-
dependent, cell-type-specific way, and perturbations of Runx1
protein function blocked silencer activity mediated through
these sites. Runx1 gain of function promotes repression
through the silencer element in T cells but activation, through
the myeloid-specific enhancer, in myeloid cells. The existence
of these lineage-specific, functionally dedicated cis elements
reveals a rich system of intermodule interactions to account for
the cell-type-specific regulation of PU.1.
MATERIALS AND METHODS
Cell culture. Adh.2C2 and EL4 cell lines were grown in RPMI medium
supplemented with 10% fetal bovine serum, penicillin-streptomycin–glutamine,
nonessential amino acids, sodium pyruvate, and 2-mercaptoethanol. RAW 264.7
and NIH 3T3 cells were grown in Dulbecco’s modified Eagle’s medium with 10%
fetal bovine serum, penicillin-streptomycin–glutamine.
DNase I HS mapping and Southern blot analysis experiments. DNase I
hypersensitivity (HS) assays were carried out as described previously (23) with
slight modifications. Briefly, about 100 million cells were harvested and washed
three times with RS buffer (10 mM Tris-HCl [pH 7.5], 10 mM NaCl, 5 mM
MgCl2, and 2 mM CaCl2). Cells were resuspended in 0.5 ml RS buffer, mixed
with 0.5 ml 1% NP-40, and incubated on ice for 10 min. The pelleted nuclei were
washed twice with RS buffer and resuspended in 0.2 ml RS buffer. Twenty-five
microliters of nuclei suspension was digested with 25 l of DNase I (Roche) at
concentrations ranging from 0 to 40 units/ml for 5 min at 20°C. Reactions were
terminated by adding 450 l of digestion buffer (100 mM NaCl, 20 mM EDTA
[pH 8.0], 6 mM EDTA, 0.5% SDS) containing 100 g of RNase A and incubated
for 30 min at 56°C. Proteinase K was then added to 0.1 g/l, and the mixture
was incubated at 56°C overnight. The genomic DNAs were then extracted by
using phenol-chloroform, precipitated with ethanol, and resuspended in 50 l of
H2O. All obtained DNAs were digested with different restriction enzymes to
completion according to the regions analyzed, and fragments were resolved by
gel electrophoresis and transferred to a nylon membrane. Probes were amplified
by PCR from the mouse genomic DNA using the primer sets in the selected
regions. The PCR products were gel purified using the Qiagen gel extraction kit
and radiolabeled by random priming. The filter was incubated in prehybridiza-
tion solution (6 SSPE [1 SSPE is 0.18 M NaCl, 10 mM NaH2PO4, and 1 mM
EDTA {pH 7.7}], 5 Denhardt’s solution, 0.25% SDS, 100 g/ml denatured
salmon sperm DNA) in a heat-sealed plastic bag at 42°C for 4 h with agitation.
The labeled DNA probe was denatured by heating at 100°C for 10 min, quickly
chilled on ice, and added to the prehybridization solution in the plastic bag. After
16 to 24 h of incubation, the filter was washed first in wash buffer 1 (2 SSC [1
SSC is 0.15 M NaCl plus 0.015 M sodium citrate], 0.5% SDS) for 15 to 20 min
at room temperature and then in wash buffer II (0.2 SSC, 0.5% SDS) twice at
65°C for 1 h. The filter was then wrapped in a plastic bag and exposed to film at
80°C for overnight.
Cloning of reporters and expression constructs. PU.1 DNA was obtained by
PCR using the BAC RP23-20F9 construct (BACPAC Resource Center [bacpac-
.chori.org]). Reporter constructs were made by cloning PU.1 sequences into
Promega’s pGL3-Basic vector. Detailed maps of reporters and their construction
are available upon request. For scanning mutagenesis analysis, CE4A core si-
lencer fragments with M2, M14, or M5 plus M9 mutations were synthesized by
GenScript and used to construct reporters. All other L98 plus 4A-5 mutants were
made using overlap PCR to produce mutated core silencers for reporter con-
struction. L9-3mRunx was made by excising the CE4 region and replacing it with
a mutated sequence synthesized by GenScript. Runx1 dominant negative and
full-length Runx1 cDNAs were kind gifts from Janice Telfer and were cloned
into Invitrogen’s pEF1/Myc-His B vector. The Ikaros dominant negative con-
struct, Plastic, was synthesized by GenScript based on the published sequence
(27) and cloned into pEF1. The following sequence with the M5a mutation and
predicted Runx sites mutated was synthesized by GenScript and used to replace


























The M5a mutation in L93-M5-mRunx was corrected by PCR mutagenesis to
generate L93mRunx. The M5 mutation was introduced into L93-M5 by overlap
PCR of CE4, which was then used to replace the wild-type sequence. Sequences
of primers used to construct reporters are available upon request. All reporter
construct sequences were verified.
Transfections and luciferase assays. Cells were transfected in some experi-
ments with FuGENE 6 reagent, at a FuGENE:DNA ratio of 3:1. Alternatively,
cells were transfected by using Nucleofection (Lonza/Amaxa). Solution-V kits
were used when nucleofecting Adh.2C2 cells with program D-19 or RAW 264.7
cells with program D-32 (Lonza/Amaxa). EL4 cells were nucleofected with So-
lution-L kits and program C-09. Cells were harvested 48 h post-FuGENE
treatment or 24 h post-nucleofection treatment. Cells were cotransfected with
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pRL-CMV, and lysates were analyzed using Promega’s dual luciferase system.
Three to 6 g Sfpi1 reporter was used in transfection mixtures with 100 to 200 ng
pRL-CMV control. For stable transfections, Sfpi1 reporters were linearized with
NotI prior to transfection. The Renilla luciferase was cloned into Invitrogen’s
pTracer EF/blasticidin A and the construct was linearized for mixed transfection
with the Sfpi1 reporters. After transfection, cells were aliquoted into six-well
plates and then selected with 5 to 15 g/ml blasticidin for their duration in
culture, beginning 1 day posttransfection. The pTracer-Renilla control was lin-
earized with FspI. Ten micrograms of Sfpi1 reporter was transfected with 1 to 2
g of pTracer-Renilla. For some stable transfections, insert copy number was
determined by quantitative PCR with primers specific to firefly luciferase and the
pTracer-Renilla control vector’s green fluorescent protein (GFP)-blasticidin se-
quence: Luc-F, ACGATTTTGTGCCAGAGTCC, and Luc-R, AGGAACCAG
GGCGTATCTCT; GFP/Blast1-F, GTCAGTGGAGAGGGTGAAGG, and
GFP/Blast1-R, ACGGGAAAAGCATTGAACAC. Expression in stable trans-
fectants was approximately linear with copy number for all constructs tested, so
this measurement was omitted in later experiments. All antisense morpholino
transfections were performed by nucleofection with 2 nanomoles of morpholi-
nos. The following morpholino antisense oligos were ordered from Gene Tools,
Inc.: anti-Runx1, CAGGCAGGAGTACCTTGAAAGCGAT; anti-PU.1, GAG
GACCAGGTACTCACCGCTATG; anti-CBF, CCTCCCCAACCGCCTCAC
CTCGCAC.
Transcription factor binding site predictions. TRANSFAC analysis was used
to predict potential transcription factor binding sites. The Biobase TRANSFAC
suite’s MATCH tool was used for the analysis. Matrix similarities of 0.925 are
shown.
Gel shift assays. Nuclear extracts were prepared by hypotonic swelling in
buffer A, followed by NP-40 lysis, nuclei pelleting, and extraction with buffer C
containing protease inhibitors (no. 11873580001; Roche). Buffer A contained 10
mM HEPES (pH 7.9), 60 mM KCl, 1 mM dithiothreitol (DTT), 0.1 mM EDTA,
0.1 mM EGTA, followed by addition of NP-40 to 0.625%. Buffer C contained 20
mM HEPES (pH 7.9), 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT.
Protein was quantified by the Bradford method. Gel shifts were performed with
6 g extract in a 30-l volume containing 1 to 2 g poly(dI-dC) and final
concentrations of 15 mM HEPES (pH 7.9), 80 mM NaCl, 15 mM KCl, 0.02 mM
EDTA, 1 mM DTT, and 3% glycerol. Five-picomole aliquots of probes were end
labeled with T4 polynucleotide kinase followed by purification with G-50 col-
umns (no. 100609; Roche). Complexes were allowed to form for 10 min with
competitors prior to addition of radiolabeled probes. After probe addition,
samples were incubated for an additional 30 min. All incubations were carried
out on ice. Complexes shown below in Fig. 6D were resolved by 4% PAGE, run
at a constant 350 V for 4 h. All other complexes were resolved by 6% PAGE run
at a constant 350 V for 2.5 to 3.5 h. All gels were run at 4°C with 0.5
Tris-borate-EDTA (TBE) gels and 0.25 TBE running buffer. Gels (4%) were
prerun for 30 min. Quantification was performed with a phosphorimager and
ImageQuant 5.2 analysis. Runx1 N-terminal antibody was from Calbiochem
(catalog no. PC284). Runx1 antibody against amino acids 231 to 245 was from
Active Motif (catalog no. 39000). A pan-Runx antibody was a kind gift from
Masanobu Satake (Tohoku University, Sendai, Japan). Ikaros (sc-13039), Myb
(sc-516), and Ets2 (sc-351) antibodies used in gel shift assays were from Santa
Cruz Biotechnology.
Western blot assays. Nuclear extracts were mixed with 2 Laemmli sample
buffer, boiled, and then run on an 8% SDS-PAGE gel. Gels were transferred to
Immobilin (Millipore) by semidry transfer. Blots were blocked with 5% milk in
TBS-T (Tris-buffered saline, 0.5% Tween 20) and then incubated overnight with
primary antibody at a 1:3,000 dilution. After washing, blots were incubated for 90
min with secondary antibody at a 1:3,000 dilution, washed, then incubated with
substrate (SuperSignal, catalog nos. 1859675 and 1859674; Pierce). Substrate was
drained from blots and then blots were exposed to film. Primary Runx1 antibody
PC284 was from Calbiochem. Sp1 antibody was from Santa Cruz Biotechnology
(sc-59).
ChIP assays. Chromatin immunoprecipitation (ChIP) assays were performed
as recommended by Upstate Biotechnology (Millipore). Briefly, 2  107 to 3 
107 cells were fixed with 0.33 to 1% formaldehyde for 10 to 30 min and then lysed
in 0.8 ml with protease inhibitors. Lysate was sonicated to produce an average
fragment size of  250 bp. Lysate (130 l) was diluted and used for each ChIP
sample with 9 g of antibody. Cross-linking was reversed by overnight incubation
at 68°C. Proteinase K digests were for 30 min at 55°C. DNA was purified by
ethanol precipitation and resuspended in 100 l water. Analysis of recovered
DNA was performed by SYBR green-based quantitative PCR (QPCR) with an
AB 7900HT apparatus. One microliter of purified DNA was used per 10-l PCR
mixture, tested in triplicate. Whole thymi from Rag2/ mice were excised, and
thymocytes were recovered by cutting and scraping thymic lobes through steel
mesh. Thymocytes were then immediately fixed and processed for ChIP assays.
Approximately 4  106 thymocytes were used per ChiP assay. Runx ChIPs were
performed with an equal mix of antibodies from Calbiochem and Active Motif
(described above). Rabbit Ig (sc-2027) and GABP (sc-22810) antibodies were
from Santa Cruz Biotechnology. Primer pairs used for analysis of ChIP-enriched
DNA by QPCR were the following: CE1-F, AGCTCAGCTGGATGTTAC
AGG, and CE1-R, AGATGGTCACACATCCCAAAG; 2kb-F, TTCTCAC
ATCCCAGACCATTC, and 2kb-R, CGCCAGCAGTTGTAGTTCTTC;
2.8kb-F, GCAGCTCACTGCTCCAAGTT, and 2.8kb-R, GAGACGGGG
AGTGGGTATGT; CE3-F, TGGAGCTCTGAGGGGCCTAA, and CE3-R,
GGCTGGGAAAGCTGACCATAA; 8.4kb-F, AGAGGAGCTGACATTGG
CATAC, and 8.4kb-R, TGAGCCTCTGAAGTGGCTTTAT; CE4B-F, AGC
AAAGCCTGTGGGAGATT, and CE4B-R, ATACCTTGGAGGCCTGTGCT;
CE4A-F, GGAAGCAGCTCTTGTCCTTGG, and CE4A-R, TCACCTCCTGG
CCACATCACT; CE5-F, GCTCTGAAAAGCACCGTTTCC, and CE5B-R, CT
GTGTTGGACCTGCAAGGAGT; 11.8kb-F, CTCTGCCCGCTCTTAAC
CTT, and 11.8kb-R, GATCTGACACGGGGATGAAA; CE76-F, CACACG
GAGTCAGAGCGGGCAG, and CE76-R, AGGAAAGAGGAAGCCATGGG
GAGA; CE8-F, AGGCAGAGCACACATGCTTC, and CE8-R, CTTCTGGGCA
GGGTCAGAGT; CE9-F, CAGGAGAGGCAGGAGGAAGGA, and CE9-R, AG
AGAGCAGAGCACTTCATGGCT; 17.8kb-F, CTGGACAAGTGGAAGGTG
ACA, and 17.8kb-R, TCAGAGGGCTTCAAAGTGGA; CD4-F, TGACGGAA
GGGAGGATGTAG, and CD4-R, AGTGGGTGGGAGCTCTGTAA;
MEF2C-F, AGCACACTCAGCCTGCTCTAC, and MEF2C-R, GGTGTAAA
GGTGCTTCCTTCC; IL-7R-F, GTCTGAGCAAAAGGATTGCTG, and IL-
7R-R, GGAGCTTCAGGGAATACCAAG.
Statistical methods. In all graphs, error bars indicate standard deviations (not
standard errors of the means). All P values reported were obtained using a
two-tailed Student’s t test for comparisons as indicated (unpaired, equal vari-
ance). For values obtained in scanning mutagenesis assays (see Fig. 5D), a
Bonferroni correction for multiple comparisons was applied. Stable transfection
results, which cover orders of magnitude in dynamic range and more closely
conform to a log normal distribution, were log10 transformed before comparison
by t test.
RESULTS
The PU.1 URE is a stage-specific T-cell enhancer. A 2.2-kb
PU.1 promoter fragment could not drive reporter expression in
myeloid cells in a chromatin context but was able to do so when
joined to the 3.5-kb URE fragment. This URE failed to en-
hance promoter-driven expression in mature T cells (20). In
order to elucidate the dynamic mechanism of PU.1 silencing
during early T-cell development, we tested the regulatory func-
tion of the URE in a more immature T-cell line representing
the DN3 stage, i.e., the developmental state in which endoge-
nous PU.1 expression is actively being silenced. We made re-
porters with the PU.1 promoter, with or without the regulatory
regions of the URE (Fig. 1A). These reporters were named
L98 and L1, respectively, and were tested for activity by tran-
sient transfection into a mature myeloid cell line, RAW 264.7,
and an immature DN3-like T-cell line, Adh.2C2. As expected,
we observed L98 reporter activity enhanced by 14-fold rela-
tive to L1 in a myeloid cell line (Fig. 1B). We also transiently
transfected a more mature T-cell line, EL4, and showed that in
that case L98 failed to show enhanced activity relative to L1, as
expected from previous reports (Fig. 1D). Unexpectedly, how-
ever, the L98 construct containing the URE reproducibly
showed 3-fold-enhanced reporter expression in the imma-
ture T cells (Fig. 1C). These results suggest that the activity of
the URE is not exclusively repressive in T cells, but rather is
developmental stage dependent.
Cell-type-specific patterns of DNase hypersensitivity asso-
ciated with conserved regions outside the URE. To look for
other cis-regulatory elements that may contribute to PU.1 si-
lencing in immature T cells, we used multigenome sequence
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alignments to find other conserved noncoding elements across
the 50-kb PU.1 mouse locus (Fig. 1A). Besides the elements
of the promoter (CE1) and the two previously identified within
the URE, which we have termed CE9 and CE8, our alignments
revealed other conserved regions, mapping from about kb
12.5 to kb 7.5 upstream of the Sfpi1 transcriptional start
site, and these regions were designated CE7, CE6, CE5, CE4
(A	B), and CE3.
To assess whether any of these regions might show cell-type-
specific differences in accessibility or transcription factor en-
gagement, a range of hematopoietic cell lines, including my-
eloid (32D), multipotent progenitor (FDCP-mix and EML-c1),
and pro-T-cell (Adh.2C2) lines were tested to map DNase HS
sites across the 5
-flanking region and first two introns of Sfpi1
(Fig. 1E and F and 2). One DNase HS site related to the
promoter was only formed in PU.1-expressing cells, as earlier
FIG. 1. The Sfpi1 upstream region contains novel cis-regulatory elements. (A) Sfpi1 multigenome alignment from exon 1 to 15 kb upstream.
Schematics of regions used in reporters are shown. (B and C) The CE9 to CE8 (URE) region is an enhancer in the RAW 264.7 myeloid cell line
and in the immature DN3-like Adh.2C2 pro-T-cell line. The Renilla luciferase-expressing control vector pRL-CMV, was used as an internal
standard. The empty pGL3-basic vector was used as a control (LB). The average relative light units (RLU) of triplicates from a representative
experiment are shown with standard deviations. (D) The CE9 to CE8 region does not possess enhancer activity in a mature T-cell line, EL4. Data
shown are the averages of three independent experiments performed in duplicate with standard deviations. (E) Novel DNase I HS sites were
identified. Probe 2 Southern blotting results for SphI-digested DNA from nuclei of indicated cell lines, with or without DNase I, are shown. For
sites at and downstream of promoter, see Fig. 2. Bands are defined by sites of DNase I sensitivity. The right panel, more extensively digested, shows
a T-cell-specific doublet of HS sites at 2 kb from SphI site (box). (F) A schematic summarizing HS mapping with various probes. S, SphI; H,
HindIII; E, EcoRV. (G) The L5-3 reporter showed lineage-specific activity. RLUs were normalized to L1. The average RLU of triplicates from
a representative FuGENE transfection experiment are shown, with standard deviations.
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reported (20). An HS site at kb 14 was previously identified
(20) to mark the URE and was detected in all the hemato-
poietic cell lines tested (Fig. 1E, band at 9.6 kb). Also
confirmed were two reported sites in the second intron,
which were seen in both PU.1-expressing and -nonexpress-
ing cell types (1) (Fig. 1F and 2). In addition, five new sites
were found. Two novel DNase HS sites formed to varied
extents in all the cell lines tested (Fig. 1A and E, black
arrows). The first of these was found at kb 12.3, near CE7
and CE6. This site is just downstream of the boundary of the
3
-URE fragment. The second cell-type-nonspecific HS site
was seen at kb 8.8, between CE4A and CE4B. Of more
interest, two other upstream DNase HS sites were detected
only in PU.1-expressing cell lines (Fig. 1A and F, red ar-
rows). These two HS sites were found at kb 10.8 and kb
7.4 (5-kb and 1.6-kb bands in Fig. 1E), flanking CE5 and
CE3, respectively. Notably, we also detected a doublet of
DNase HS sites specific to immature T cells, at kb 8.5 (Fig.
1A and 1F, blue arrow, and E, right, band around 2 kb), and
not seen in any of the PU.1-expressing cell types. We hy-
FIG. 2. DNase HS mapping detected HS sites in the first two Sfpi1 introns. (A) The pro-T-cell line scid.adh lacks HS sites downstream of exon
1 (E1). Probe 3 (P3) was used in a Southern blot assay of EcoRV-digested DNA from nuclei of the indicated cell lines, with or without DNase
I. Bands correspond to sites of DNase I sensitivity. Size markers are shown. The schematic depicts HS mapping results with probe 3. Red arrows
indicate HS sites detected in PU.1-expressing cells and correspond to the bands in the Southern blot. S, Sph I; H, Hind III; E, EcoRV. (B) Similar
DNase HS sites were detected across intron 2 in PU.1-expressing cells and also weakly in a nonexpressing pro-T-cell line (scid.adh). Probe 3 was
used in a Southern blot assay of Sph I-digested DNA, with or without DNase I, as described above.
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pothesized that a regulatory feature associated with Sfpi1
silencing could be near this region.
Identification of a novel cell-type-specific PU.1 regulatory
element with T-lineage-repressive activity. Reporters were
made as shown in Fig. 1A to test if any conserved elements
from CE7 to CE3 might have regulatory activity independent
of the URE in immature T cells. The L7-6 construct was made
to combine the Sfpi1 promoter with a 2-kb region including
CE7 and CE6, where an overlapping non-cell-type-specific HS
was found in myeloid and T cells (Fig. 1A). L7-6 showed
enhanced and nonspecific activity in both myeloid and imma-
ture T-cell lines, with 2-fold increased activity in transient-
transfection assays, compared to L1(Fig. 1G, gray versus black
bars). In contrast, a construct containing the promoter plus the
new conserved elements from CE5 through CE3, L5-3, showed
activity that was clearly cell type specific. L5-3 was strongly
repressed in the Adh.2C2 cells compared to L1 (Fig. 1G, gray
versus blue bars). Strikingly, the same L5-3 construct was
found to have enhanced activity in RAW 264.7 cells. In sum-
mary, the conserved sequences CE9 to CE6 span a region of
4 kb and contain multiple regulatory elements that increase
promoter activity in both myeloid and immature T cells. In
contrast, the 3-kb region containing CE5 to CE3 was found
to mediate cell-type-specific activating or repressive regulatory
function.
The regulatory elements in CE5 to -3 not only showed lin-
eage-specific effects on promoter activity, but also strongly
modulated the combined activity of the promoter and the
URE. These effects were strongest when the reporters were
stably integrated and expressed from a chromatin context in
myeloid and immature T-cell lines. We stably transfected lin-
earized reporters containing elements CE9 to CE6 (L9-6) or a
longer sequence extending further to include CE9 to CE3
(L9-3). The L9-6 reporter efficiently expressed luciferase when
stably integrated into chromatin, as expected, giving similar
levels in myeloid cells (Fig. 3A) and in our DN3-like immature
T-cell line (Fig. 3B). The CE9 to -6 enhancer activity was
hematopoietic specific, as the L9-6 reporter generated a 100-
fold increase in luciferase expression in both myeloid and im-
mature T cells compared to nonhematopoietic NIH 3T3 fibro-
blasts (Fig. 3C).
The addition of the CE5 to CE3 region to L9-6 to make the
L9-3 construct yielded sharply different results. This construct
gave an 8-fold increase in reporter expression in myeloid
FIG. 3. The CE5 to CE3 region has cell-type-specific regulatory functions in stably transfected cells. A schematic of the reporters used is shown.
Data are reported as the relative light units (RLU) per insert copy number. (A) Extension of L9-6 to include the CE5 to CE3 region increases
activity in RAW 264.7 myeloid cells. (B) Inclusion of the CE5 to CE3 region silences activity in immature Adh.2C2 T cells. (C) Background activity
of reporters in the nonhematopoietic NIH 3T3 fibroblast cell line. Dots represent independent wells containing multiple founders, and bars show
the geometric mean for the wells. *, P  0.001 in two-tailed t test comparisons of log10-transformed data.
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cells compared to L9-6 (Fig. 3A). In the T cells, however,
addition of CE5 to CE3 repressed reporter expression to a
level comparable to the background level in NIH 3T3 fibro-
blasts (Fig. 3B and C). These data show that the CE5 to CE3
cis-regulatory region can contribute to a 500-fold difference
in reporter expression between myeloid and immature T cells.
Mapping of a bipartite region necessary for silencing in a
chromatin context and a core silencer sufficient for silencing
in transient assays. DNase HS mapping revealed a pan-hema-
topoietic HS site between CE4A and CE4B, as well as a T-
lineage-specific HS site just downstream of CE4B (Fig. 1A, E,
and F). This suggested that the CE4A-B region might be in-
volved in the T-cell silencing effect. As shown in Fig. 3B,
deletion of CE4A and CE4B did abolish the repressive func-
tion within the L9-3 construct. To map regions within CE5 to
CE3 that contribute to the cell-type-specific regulatory func-
tion, we made more reporters by combining individual con-
served regions together with the 2.2-kb PU.1 promoter and
then tested their function in transient-transfection assays.
While the dynamic range of these assays is far less than in the
stable transfections, these rapid surveys yielded results that
could be verified in the stable transfectants.
This functional mapping showed that the myeloid-enhancing
activity and the pro-T-cell silencing activity are mediated by
different cis-regulatory sequences. The CE5 region confers my-
eloid-specific enhancer activity. As shown in Fig. 4B, CE5 (in
L5) was able to enhance promoter activity by 7-fold in my-
eloid cells, but by only 1.5-fold in the immature T cells (Fig.
4C). In contrast, all the repressive activity in immature T cells
mapped to the CE4 region. Results with the L4A construct
showed that the CE4A region alone could repress Sfpi1 pro-
moter activity in the immature T cells (Fig. 4C), but with little
or no effect in the myeloid cells (Fig. 4B). The CE4B region did
not confer independent regulatory function in transient assays
(Fig. 4B and C), although it contains one reported Stat3 site
implicated in Sfpi1 induction by cytokines (14). However, the
presence of both CE4A and CE4B was necessary for full silencing
when integrated stably in a chromatin context (Fig. 4D), indicat-
ing that the CE4A-B region is a bipartite T-specific silencer.
The CE4A region spans 450 nucleotides (nt) in which the
central 120 nt are most conserved. To map the sequences
within the CE4A region that are vital for silencing, we trun-
cated this 450-nt region and made reporters with these trun-
cations flanked by the UREs and promoter (Fig. 5A). These
experiments showed that a minimal conserved core is neces-
sary and sufficient for repression in the transient assays (Fig.
5B). Construct L98 plus 4A-5, containing only the minimal
core silencer region of 120 nt from CE4A, was sufficient to
repress the enhancer activity of the CE9 to CE8 region in
immature T cells (Fig. 5B).
Scanning mutagenesis analysis of the core silencer. The
CE4A core silencer mapped to a peak of conservation identi-
fied by the multigenome alignment (Fig. 1A). The precise
nucleotide alignment is shown in Fig. 5C, with asterisks mark-
FIG. 4. T-cell- and myeloid cell-type-specific regulatory activities map to distinct regions within the CE5 to CE3 fragment. (A) Diagram of the
CE5 to CE3 truncations used in transient-transfection experiments. (B and C) Myeloid enhancer activity mapped to the CE5 region. T-cell silencer
activity mapped to the CE4A region. Representative experiments, with relative light units (RLU) normalized against L1 (with standard deviations)
are shown. (D) Both CE4A and CE4B contribute to silencing in a chromatin context. The diagram shows reporters used for stable cell lines. Data
points are as described for Fig. 3. Data are shown as RLUs. *, P  0.007 in two-tailed t test comparisons of log10-transformed data.
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ing nucleotides that are 100% conserved among 11 organisms
and with predicted transcription factor binding sites shown
(see Materials and Methods). To unmask the most influential
repression sites in an unbiased way we carried out scanning
mutagenesis and tested for loss of repression in transfection
assays, mutating 6-nt blocks (M1 to M15) (Fig. 5C) across the
core CE4A silencer region within the reporter construct L98
plus 4A-5. Mutants M1 to M4 did not affect the repressive
function of the core silencer (Fig. 5D). However, mutants M5
to M9 caused a loss of core silencer function (Fig. 5D). These
mutants span a region of 30 nt across the largest conserved
block within the core silencer (Fig. 5C). Another mutant, M13,
also blocked core silencer activity (Fig. 5D). Close examination
of the sequences where mutations abolished core silencer func-
tion showed that 5/6 mutations, M6 to M9 and M13, overlap
sequences with 90% similarity to the canonical Runx binding
motif, (Py)G(Py)GGT (Fig. 4C, red boxes). Mutant M5 does
not overlap a predicted Runx site, but it does cross a conserved
site, “site X,” predicted to contain an Ets family target site
(Fig. 5C, blue box).
Identification of T-cell-specific protein complexes. To iden-
tify transcription factors vital for the T-cell-specific repressive
activity of the CE4A core silencer, probes spanning the CE4A
core region were used in gel shift assays with nuclear extracts
from Adh.2C2 and RAW 264.7 cells to determine the nature of
cell-type-specific protein-DNA complexes. Complexes were
identified by mobility and by cross-probe competition and an-
tibody treatments. These assays showed that at least three
regions of the CE4A and -B elements could nucleate cell-type-
specific protein-DNA complexes that differed qualitatively
when formed with T-cell or myeloid extracts (Fig. 6B). The cell
type specificity of the complexes formed with these probes
contrasted with those detected by the CE8 region of the URE,
where similar patterns of complexes were formed with extracts
from T-cells and myeloid cells alike (Fig. 6C).
Figure 6D shows that a large probe spanning the whole
critical repression region (CE4A-P6) could nucleate a single
complex from Adh.2C2 extracts. This large, slow-migrating
complex (T1) depended on binding to two distinct regions, as
defined by competition with mutant and wild-type competitors.
One critical site was element X (lanes 2 versus 7), and the
other was the region of predicted Runx site CBF3 (laned 3
versus 4). To define the distinct component complexes that
might contribute to the large T1 complex and to identify those
that might be cell type specific, an overlapping series of smaller
CE4A probes were used. Two distinct T-cell-specific com-
plexes were formed on these smaller probes: one named A3
and a larger, slow-migrating complex named A1 (Fig. 6B).
Using probe CE4A-P3, which formed both complexes, Fig. 7A
shows that the sequence requirements for these two complexes
can be dissociated. Complex A3 mapped to site X, which is
mutated in CE4A-P3m5a, while complex A1 depended on the
region of the CBF3 site that is mutated in CE4A-P3m7a.
Because the full silencing activity in a chromatin context
FIG. 5. T-cell silencer activity mapped to a conserved core region. (A) Diagram of reporters with CE4A truncations flanked by the CE9-CE8
enhancer and the promoter. (B) The L98 plus 4A5 reporter contains the core silencer sufficient for silencing (red bar). Data shown are from a
representative transient experiment performed in duplicate with Adh.2C2 T cells. (C) Multigenome alignment of the CE4A core silencer.
Nucleotides conserved in all 11 organisms are marked by an asterisk. Six nucleotide blocks mutated in the scanning mutagenesis analysis are labeled
(M1 to M15). Sequences with 0.925 similarity to TRANSFAC predicted binding sites are shown. The region affected by M5 is designated site
X. (D) Scanning mutagenesis revealed multiple sites contributing to core silencer activity. Data shown are averages from four or more independent
Adh.2C2 transfections  standard deviations, with relative light units (RLU) normalized against L98 activity. Red bars mark reporters with
mutations blocking silencer activity. *, P  0.02 (Bonferroni corrected) compared to wild-type reporter data.
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depends on region CE4B as well as CE4A, we carried out a
screen for potential T-cell-specific binding complexes to CE4B
probes too. Of seven CE4B probes tested, only two formed
complexes and only probe CE4B-P3 formed cell-type-specific
complexes (Fig. 7B). This probe was also found to form a
very-slow-moving complex, designated B1, which was T-cell
specific (Fig. 6B, lane 11, and 7B). The CE4B B1 complex was
similar to the large A1 complex formed with CE4A, based on
cross-competition and mutational analysis (Fig. 7A and C),
and both depended on the integrity of predicted Runx sites.
Both large complexes, A1 and B1, were also supershifted by
antibodies against Ikaros, although not by anti-Myb (Fig. 7A
and D,), suggesting a higher-order complex structure.
Together, the analyses suggest that the T-cell-specific bands
A1 and B1 represent T-cell-specific complexes dependent on
predicted Runx sites, while A3 is a T-cell-specific complex that
depends on site X. These may interact to form a higher-order
T1 complex. The possibility that the A1 and A3 complexes on
CE4A interact at the protein level was supported by the ability
of a pan-Runx antibody to interfere not only with T1 and A1
but also with A3 (Fig. 7E, lane 5, and 6D, lane 10). The
composition and precise role of the complexes depending on
the X site are still unresolved (data not shown). However,
further experiments strongly support direct involvement of the
Runx1 protein in the T-cell-specific repression activity of the
bipartite silencer.
FIG. 6. The CE4 region nucleates T-cell-specific protein complexes in vitro. (A) Schematic showing alignment of probes relative to the core
silencer. Wild-type probe sequences are also shown with asterisks to mark bases mutated in competitors. Sequences of the CE8 probes are also
shown. (B) Multiple CE4A probes form T-cell-specific complexes in vitro. Probes were incubated with nuclear extracts from Adh.2C2 (T) or RAW
264.7 cells (M). T-cell-specific complexes A1/B1 and A3 are indicated by arrows. (C) Unlike CE4A-P3, an Ets-Runx CE8 probe forms similar
complexes with both pro-T-cell (Adh.6D4) and myeloid (P388D1) extracts. (D) Mapping of sites contributing to “T1” complex formation on probe
CE4A-P6 by using Adh.2C2 nuclear extracts.
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The CE4A silencer contains multiple nonconsensus Runx
binding sites that contribute to T-cell-specific complexes. Al-
though similar to Runx sites, the core silencer defined by mu-
tations does not contain precise matches to the Runx consen-
sus sequence (Py)G(Py)GGT, and more evidence was needed
to determine whether Runx proteins could be part of com-
plexes A1, B1, and T1. The pan-Runx antibodies shifted or
inhibited these complexes and Runx1-specific antibodies
seemed to cross-link them, but the slow initial mobility of
these complexes made the results difficult to interpret (data
FIG. 7. Cross-reactive, pro-T-cell-specific complexes formed at the CE4A and CE4B regions. CE4B can nucleate a pro-T-cell-specific complex in vitro
and can cross-compete with the T-lineage-specific A1 complex formed by the CE4A region probe. (A) The sequence requirements for formation of
different T-lineage complexes on probe CE4A-P3 can be separated. A homologous probe from the CE4A region cannot compete for complex A1 if the
Runx sites are mutated (compare lanes 2 and 3), indicating that a Runx site is needed for A1 formation. Complexes A2 and A3 are competed by the
homologous CE4A-P3 probe, but not when the GGAA core of the Ets site is mutated (lane 4). A probe from the CE4B region competes for complex
A1 but not for complexes A2 or A3 (lane 5), and the ability to compete for A1 depends on a Runx site here as well (lanes 6 and 7). Complex A1 may
also contain Ikaros, as it can be shifted by an anti-Ikaros antibody (lane 9). (B) The CE4B-P3 probe nucleates a pro-T-cell-specific complex, B1 (lane 1;
“B”) and a myeloid cell-specific complex, B3. Complex B1 does not depend on the STAT site previously shown to contribute to PU.1 expression (lanes
3 and 4). In contrast, the myeloid complex B3 and the weaker T-lineage complex B2 do require the STAT site for formation of complexes (lanes 3 and
4 and lanes 10 and 11). (C) Complex B1 depends on the sequences spanning nonconsensus Runx and Ikaros sites (lanes 2 and 3). Probe CE4A-P3 can
be used in competition to eliminate complex B1 formation, and the ability to compete requires the Runx site (lanes 4 and 5). (D) Like A1, complex B1
can be supershifted by an anti-Ikaros antibody (lane 3). (E) Interaction of Runx factors with complexes at multiple sites in CE4A and CE4B. A pan-Runx
antibody inhibits complex formation on multiple probes by Adh.2C2 pro-T-cell nuclear extracts (red arrows, lanes 2, 5, and 15). Anti-Ets2 antibody had
no effect on any complex. (F) The sequence of probe CE4B-P3 is shown, with asterisks indicating mutated nucleotides. TRANSFAC predicted
transcription factor binding sites are shown with their matrix similarity scores in parentheses.
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not shown). Therefore, the binding of Runx proteins to
CE4A was confirmed by competition in gel shifts against a
validated Runx-dependent silencer sequence, the Cd4 si-
lencer (32) (Fig. 8).
The Cd4 silencer probe contains two canonical Runx motifs
(Fig. 9B) and formed a strong band with nuclear extract pre-
pared from Adh.2C2 cells (Fig. 8, black arrows), which was
specifically supershifted by Runx1-specific antibodies (Fig. 8A,
white arrows). The complex is competed by cold Cd4 probe,
and this competition depends on the two Runx motifs (Fig. 8A,
lane 3). Competition for this complex thus affords an assay for
Runx1 binding to other sequences. Probe CE4A-P1, although
outside the core region required for silencing, does contain a
canonical Runx motif, CBF1, and competed with the Cd4
probe for Runx binding (Fig. 8A). CE4A-P2 lacks the canon-
ical Runx motif and did not compete for Runx binding. Com-
petitor probe CE4A-P3 competed for Runx binding (Fig. 8A),
but when the potential Runx site CBF3 was mutated (Fig. 6A,
FIG. 8. Multiple Runx sites are present across the CE4A core silencer region. (A) The strong complex nucleated by the Cd4 reference probe
is dependent on Runx sites (lane 3) and can be supershifted by anti-Runx1 antibodies (lanes 13 and 14). The CE4A probes P1, P3, P4, and P5 (Fig.
6) and CE4B-P3 (Fig. 7) compete with the Cd4 probe for Runx protein binding. Competition by the CE4A-P3 and CE4B-P3 probes depends on
the integrity of their Runx sites (lanes 7 and 11). (B) The CE4A-P3 probe’s site X region is needed to compete with the Cd4 probe for Runx
binding, but the GGAA motif (Fig. 5C) is dispensable (lane 4 versus lanes 5 and 7). (C) All Runx sites across the extended CE4A-P8 probe must
be mutated to abolish competition for Runx complex formation on the Cd4 probe. Compare CE4A-P8 M-all (lane 15) with lanes 7, 9, 11, and 13.
(D) Diagram showing where the CE5, CE4A-P3, and CE4B-P3 probes are located. (E) Diagram of probes. Asterisks indicate mutated nucleotides
in competitors.
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CE4A-P3m7a), it could no longer compete for the Cd4 silencer
Runx complex (Fig. 8A). However, this is not the only site in
the CE4A region where Runx could bind. CE4A-P4 contains
predicted Runx sites CBF4 and -5 that also competed with the
Cd4 probe for Runx binding (Fig. 8A). Note that the Runx
sites in all these probes, except for CE4A-P1, map to the
locations of mutations that damaged repression in Fig. 5, i.e.,
mutants M6 to M9. The predicted CBF6 sequence in probe
CE4A-P5, which is disrupted by mutant M13, also competed
with the Cd4 probe for Runx binding (Fig. 8A). When a longer
probe that spanned the M5 to M13 regions of CE4A was used
as a competitor, mutations in at least four distinct sites were
needed to abolish all Runx competition activity (Fig. 8C, M-
all). The CE4B-P3 probe also competed against Cd4, again
indicating that this region has a Runx binding site (Fig. 8A).
These results suggest not one but multiple potential Runx
binding sites in the functionally vital regions of the bipartite
silencer.
The one mutation that affected repression in transient assays
that seemed not to alter a Runx site was the M5 mutant, a 6-bp
mutation which spans the Ets-like site we call X (Fig. 5C).
Consistent with the specificity of the assay, smaller mutations
crossing the X site did not prevent the CE4A-P3 oligo from
competing for Runx binding to the Cd4 silencer probe (Fig. 8B,
lanes 5 to 7). Thus, the GGAA core of the X site is not
required for the binding of Runx to this probe. However, the
full 6-nucleotide M5 mutation also destroys the ability to com-
pete with the Cd4 Runx complex (Fig. 8B, lane 4), implying
that the sequence between the X site and CBF3 is important to
stabilize Runx binding. Thus, all of the mutations that abol-
ished core silencer function in the scanning mutagenesis assay
are involved in formation of Runx complexes in vitro.
Quantitative impact of Runx levels on binding to the CE4A
silencer. Runx1 was already clearly known to play activating
and repressive roles in PU.1 expression (17) but was assumed
to work only through the CE8 element, where a doublet of
canonical Runx sites are separated by 50 nt from a Runx/Ets
site pair. Runx1 is expressed in myeloid, B, and T cells alike,
raising the question of how it mediates such diverse effects in
different cells. One potential mechanism could depend on
dose. Western blot analysis of Adh.2C2 and RAW 264 nuclear
extracts showed that the T-lineage cells had 4 times more
Runx1 protein than the myeloid cells (Fig. 9A). We therefore
asked whether the ability of Runx1 to bind CE4 is quantita-
tively distinct from its ability to bind CE8.
We noted that the CE4 Runx sites in functionally important
regions affected by mutants M6 to M9 and M13 all deviate
from the consensus, (Py)G(Py)GGT, unlike CE8 sites (Fig.
9B) Thus, we hypothesized that occupancy of the repression-
linked Runx sites in CE4A-4B might require higher Runx
expression levels than the sites in CE8.
We examined the binding affinities of the CE8 and CE4A-P3
Runx sites by titrated competitions against the Cd4 Runx
probe, with self-competition by cold Cd4 probe as a standard
(Fig. 9C). The regions of CE8 containing Runx sites, in probes
CE8-P1 and CE8-P3, competed equally strongly, and mutation
of the Runx sites proved that this was site specific (CE8-P1m1
and CE8-P3m1) (Fig. 9D). In contrast, the CE4A-P3 probe
was a notably weaker competitor, although it included both the
highest-scoring Runx site across the functionally important
silencer region and the adjacent X site which seemed to en-
hance Runx binding. Taken together, these data suggest that
even the most dominant Runx site in CE4A indeed has a
FIG. 9. The nonconsensus CE4A-P3 Runx site has weaker binding affinity than the consensus sites of CE8. (A) Western blot of Runx1 and Sp1
protein. The same blot was probed for Runx1 and then Sp1. (B) Sequences of Cd4 and CE8 oligos are shown. Asterisks mark bases mutated in
competitors. (C and D) CE4A-P3 binds Runx more weakly than CE8 probes. The CD4 silencer probe was used to assay Runx1 binding potential.
Competitors were used at a 100-fold excess except where indicated. Band intensity was quantified by phosphorimaging, with the background
subtracted, and data are plotted as relative intensities normalized against lane 1 (one experiment, representative of three).
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weaker binding affinity than the Runx sites in the URE and
might require higher Runx1 levels for occupancy.
Runx protein perturbations and Runx binding site muta-
tions abolish silencer function. To establish whether Runx1
itself was functionally important for the silencing mediated by
CE4A in the T-cell context, we carried out Runx1 gain-of-
function experiments in T and myeloid cells (Fig. 10A and B).
We also blocked Runx1 function two ways. First, we used
cotransfections of a Runx1 dominant negative expression con-
struct (d190) (34) together with the reporters to compete
against endogenous Runx1 (Fig. 10A). This Runx1 DN con-
struct includes the full Runx1 DNA binding domain but lacks
the C-terminal effector domains. Second, we transfected mor-
pholino antisense oligonucleotides to knock down Runx1 pro-
tein levels and morpholinos against the Runx complex partner,
CBF (Fig. 10C). In both assays, we assessed the effects of the
perturbation on CE4-dependent silencing activity by compar-
ing effects on expression of L98 with or without the silencer
(the full CE5 to CE3 region or CE4A alone). For controls,
cells were also transfected with a morpholino against PU.1
itself. Finally, to assess whether Ikaros, which also appeared to
be associated with the T-cell-specific complexes (Fig. 7A and
D), might promote silencing, we further transfected the cells
with a “dominant negative” mutant form of Ikaros called Plas-
tic (27).
Figure 10A shows that added full-length Runx1 sustained or
intensified repression mediated by the CE4 silencer in T-lin-
eage cells, whereas competition with Runx1 DN dramatically
blocked repression. Figure 10A shows the clear enhancer ac-
tivity of the CE9 to CE8 URE in the T cells, which was
FIG. 10. Runx perturbations abolish silencing activity in immature T cells (Adh.2C2). (A) Cells were nucleofected with PU.1 reporters, plus
1 to 2 g of the indicated plasmid. Only cotransfection with the Runx dominant negative expression vector relieved silencing (red bars). (B) Runx1
overexpression in RAW 264.7 cells enhances CE5 to CE3 activity and does not lead to repression. *, P  0.03. Data are from three experiments
performed in duplicate and are reported relative to L1 activity. (C) Western blot of whole-cell lysates from Adh.2C2 cells transfected with or without
Runx1 morpholino, showing Runx1 loss. (D) Antisense morpholino knockdown of endogenous Runx1 blocks silencing (red bar). Data from two
independent experiments are shown as the L98	4/L98 reporter activity ratio. *, P  0.02 compared to the no-morpholino data set. (E) Runx sites are
essential for silencing in a chromatin context in stably transfected Adh.2C2 cells. With L93 mRunx, all predicted Runx sites in the CE4A-B region
mutated. L93 M5, L93 with the M5 mutation; L93 mRunx M5, mutations combined. Data are plotted as for Fig. 4D with data from two independent
experiments, each with four to six independent mixed pools of stable cells. *, P  0.001 compared to L96; #, P  0.001 compared to L9-3.
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eliminated by inclusion of the CE5 to CE3 regions (Fig. 10A,
lanes 11 and 12 versus lanes 3 and 4). Cotransfection with the
dominant negative Plastic mutant of Ikaros or exogenous full-
length Runx1 had no effect. However, cotransfection of the
Runx1 DN relieved silencer activity in a dose-dependent way
(Fig. 10A, red bars). Some repression-alleviating effect of the
Runx1 DN was also detectable when assayed with the L98
reporter, consistent with evidence that endogenous Runx1 can
be repressive at CE8 as well (17); however, this effect was much
weaker than when the CE5 to CE3 region is present.
The effect of Runx1 and the general potency of the CE4
element were both cell type specific. We also tested Runx1
overexpression on reporter activity in myeloid cells and found
that added Runx1 exerts only a weak repression effect on
constructs containing CE4. This effect is dwarfed by its aug-
mentation of the enhancer function of CE5 to CE3 (Fig. 10B),
reflecting possible action through stimulatory Runx sites
present in the CE5 element.
Endogenous Runx1 protein in the Adh.2C2 cells could be
knocked down by transfection with an antisense morpholino
(Fig. 10C). This treatment also blocked silencer activity of
CE4A, as measured by the ratio of expression driven by L98
plus the CE4 element to expression driven by L98 alone (Fig.
10D). As Runx1 binds DNA in a heterodimer with CBF, a
morpholino was made to block CBF expression, and this also
relieved some repression (Fig. 10D). All these effects were cell
type specific. In contrast, a morpholino against PU.1 had no
effect, nor did a control morpholino against the inverse of the
Runx1 sequence.
Finally, the role of the Runx sites in silencing was confirmed
in stable transfections by testing the L9-3mRunx reporter in
which all predicted Runx sites across CE4A-B were mutated. The
impact of the M5 mutation in L9-3 was also evaluated, alone and
in combination with mRunx (L9-3 M5 mRunx), as the X site
stabilized Runx1 binding in vitro. As shown in stably transfected
cells, the L9-3mRunx reporter, with or without the M5 mutation,
could no longer be silenced in Adh.2C2 cells (Fig. 10E). In con-
trast, the L9-3 M5 construct, which retains all Runx sites but has
the M5 mutation, was still moderately silenced.
Runx1 binds to the CE4A core silencer in vivo specifically in
immature T cells. These results raised the question why Runx1
could exert repression via CE4 in T cells but not in myeloid
cells. To determine whether Runx1 recruitment to CE4 was
lineage specific, we carried out ChIP assays against Runx1 on
chromatin from RAW 264.7 and Adh.2C2 cells. The results
confirmed that Runx1 binding on CE4A is cell type specific in
vivo (Fig. 11A and B). No strong Runx1 binding was detected
across any part of the PU.1 upstream region in the myeloid
cells (Fig. 11A, right), consistent with evidence that it may act
there in a hit-and-run style (16). In contrast, there was a strong
peak of Runx1 binding at CE4A in the immature T-cell line,
stronger than its binding to the URE (Fig. 11B, right). The
disparity between strong Runx1 binding at CE4A and weaker
signals at CE8 in the T cells was unexpected in view of the
established activity of Runx at CE8 and the open chromatin at
CE8 in T and B cells alike (15), but this was highly reproduc-
ible. Both T and myeloid cells showed similar binding of the
Ets family factor GABP to CE8 (Fig. 11A and B, left panels),
confirming that protein-DNA complexes could be detected at
CE8 at least as efficiently in the T cells as in myeloid cells, if
they were there. Thus, in immature T cells but not in myeloid
cells Runx1 is selectively recruited to CE4A, even more than to
the URE, consistent with a role in T-cell-specific silencing
activity of this element in vivo.
Runx1 binding to CE4 also occurs in normal T-cell precur-
sors at the stage when they first turn off PU.1 expression, as
shown by ChIP assays on chromatin of primary thymocytes
from Rag2/ mice. These are populations in which 90% of
cells are blocked in vivo at the pro-T-cell DN3 stage and have
newly silenced Sfpi1. Runx1-specific antibodies were strongly
enriched for CE4A in Rag2/ thymocytes, at least as strongly
FIG. 11. Runx1 binds the CE4A silencer region in vivo in T cells. A
schematic of the PU.1 upstream region with conserved elements and
their approximate location is shown. (A and B) ChIP assays in RAW
264.7 cells (A; red) and Adh.2C2 (B; green). The left panel shows
ChIP analysis with antibody against the Ets factor GABP. The right
panel shows the Runx1 ChIP. Results shown are from three or more
independent experiments. (C) ChIP assays with Ig failed to enrich any
region in Rag2/ thymocytes (left panel). ChIP assays demonstrated
Runx1 binding to the CE4A core silencer in primary thymocytes (right
panel). Runx binding to the CD4 silencer is shown for comparison
(green bars). Results shown are from two independent experiments.
Standard deviations are shown (error bars.).
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as CE8 (Fig. 11C). The magnitude of enrichment was compa-
rable to the enrichment of the Cd4 silencer in these cells, an
internal positive control, because Runx1 is known to repress Cd4
at this stage of development (33) (Fig. 11C). Thus, Runx1 is
recruited to CE4A preferentially and lineage specifically under
physiological conditions within primary T-cell precursors.
DISCUSSION
A challenging mechanistic question has been how all the
intricate lineage-specific regulation of PU.1 could be achieved
through the only two fairly simple cis-regulatory elements
known for the Sfpi1 gene, the promoter and the URE. The
problem has been intensified by accumulating evidence that
has shown the same factor, Runx1, to be both a major positive
and negative regulator for the Sfpi1 gene, yet apparently both
are through the fixed context of the URE sites (Fig. 12A).
Additional mechanisms recently shown to modulate PU.1 ex-
pression, such as antisense transcription (11) and miRNA sup-
pression (36), have explained only modest differences in the
level, inadequate to account for the 2 to 3 orders of magnitude
of repression that Sfpi1 undergoes during T-lineage commit-
ment. Here, we have shown that the true regulatory system for
this gene is more complex, involving deployment of multiple,
functionally dedicated, conserved elements of Sfpi1 that can
mediate developmentally lineage-specific transcriptional regu-
lation. We propose that it is the modulation of URE function
by dominant enhancing or repressive inputs at these elements
that yields the richness of developmental regulatory patterns
for this crucial gene (Fig. 12B).
The nature of these new elements contrasts with the roles
proposed for the promoter and the URE, which are essentially
bifunctional. The new elements seem specific not only for
context-dependent activity but also for valency of function, i.e.,
activation versus repression. They correspond to conserved
sequences and are thus likely to have been evolutionarily se-
lected for these functions. Although the factors that bind these
new modules include ones like Runx1, which also binds to
three conserved sites in the URE, our results show that the
new element CE4A can provide these factors with an alterna-
tive site organization and an alternative selection of interaction
partners. Thus, at CE4A and CE4B, Runx factors participate
in cell-type-specific complexes that they do not generate at
FIG. 12. Schematic showing proposed cell-type-specific interactions between the URE (CE8/9) and novel elements CE5 and CE4. (A) Current
model of Runx1 dosage-independent bifunctional URE-regulated PU.1 expression. (B) Revised model of Runx1 dosage-sensitive PU.1 regulation.
For full details of factors known to bind the promoter and URE, see reference 15.
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CE8 (Fig. 12B). These alternative complexes, organized by
binding to the distinct cis-regulatory DNA “scaffolds,” are
likely to explain why the impact of Runx1 binding at sites like
CE4A can be focused on mediating a repressive transcriptional
response.
Identification of novel regulatory elements was needed to
explain the early repression of Sfpi1 during T-cell develop-
ment, because the Sfpi1 UREs CE9 and CE8 retain their
enhancer function in an immature DN3-like T-cell line even
though they lose enhancer function in more mature T cells.
The residual expression of PU.1 observed in URE hemato-
poietic cells (29) already implied the existence of additional
positive regulatory sites outside the URE. Our results in fact
identify at least two novel, conserved cis-elements: one that can
act as an enhancer in myeloid cells at about kb 10, CE5, as
well as the bipartite CE4A plus -4B element that mediates
profound silencing in immature T cells, 9 kb upstream of the
Sfpi1 transcriptional start site. At least CE4A appears to be
fully T-cell specific in its function and a selective mediator of
negative regulation.
The discovery of CE4 and the ability of this element to exert
dominant silencer activity over continued URE enhancer func-
tion in immature T cells together offer an elegant explanation
for how the dual functionality of the URE is temporally
switched in T-cell development. We show that Runx1 in these
immature T cells is dose limiting for the effect of this silencer,
that Runx1 binds to the CE4A and CE4B regions, and that its
sites in the CE4A conserved element are crucial for repressive
function of the silencer. In vivo, Runx1 rises to its highest level
in immature T cells at the DN3 stage, just as PU.1 expression
is first shut off (21, 32). T cells then continue to express one or
more of the Runx family members throughout their continued
development and mature function, potentially preserving the
silence of PU.1 by active repression. Even if this were not the
case, the Runx-dependent silencing of the Cd4 gene provides a
precedent for a hit-and-run silencing mechanism that Runx
proteins can use for lasting effects (33).
Nevertheless, Runx1 is clearly not T-cell specific, and so its
effectiveness at the CE4 silencer must be subject to other
conditions. Its selective recruitment to the CE4 repression
module in T cells likely depends both on increase of Runx1
beyond a dose-dependent threshold, from our evidence that
the silencer Runx1 sites are relatively weak, and also on inter-
action with a T-cell-specific repression cofactor. The evidence
for the latter is indirect, based on two findings. First, Runx1 is
recruited to the CE4 element in T cells more strongly than to
the CE8 element, even though individual Runx binding sites in
CE8 are “stronger.” This could be explained if Runx1 inter-
acted with a partner that binds at CE4 but not at CE8. Our
results suggest that a T-cell-specific partner might bind at the
site X region of CE4A, a region that has an effect on Runx
binding affinity as well as on repression in the context of the
whole silencer. Clearly, the factor or complex that binds here is
of great interest. One motif within site X suggests that a T-cell-
specific Ets family factor could be involved, but to date this has
been impossible to confirm with a large range of antibodies
tested in both gel shift and ChIP assays (M. Zarnegar, unpub-
lished data). However, note that a critical mass of Runx1 bind-
ing is still required in order to mediate repression and that in
the most rigorous stable transfection assays, the multiplex
Runx sites can mediate silencing in the absence of the X
element.
Formally, the T-cell-specific recruitment of Runx factors to
CE4 could depend on the removal of an antisilencing factor.
Against this possibility is the evidence that the CE4 region
shows more “open” histone marks in T cells than in myeloid or
FIG. 13. CD4	 T-cell ChIP-seq experiments suggested open chromatin across CE4 in normal, mature human T cells. H3K4me2 ChIP-seq data
are borrowed from Barski et al. (5) (http://dir.nhlbi.nih.gov/papers/lmi/epigenomes/hgtcell.aspx). CE4 is marked by H3K4me2 to a similar extent
as the UREs.
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B cells (M. Zarnegar, unpublished results). The CE4 region is
marked by H3K4m1 and H3K4me2 even in mature CD4	
human T cells, as defined in ChIP-seq studies (5) (Fig. 13).
Nevertheless, it is interesting that the CE4B region includes a
Stat3 binding site shown to mediate Sfpi1 activation (13). The
Stat3 site does not overlap but is adjacent to the sites needed
for complex B1 formation, and it is possible that Stat3 mobi-
lization by growth factor receptors such as Flt3 or gp130 could
prevent assembly of the silencer complex until a key stage of
T-cell development and until inflammatory cytokines are ab-
sent.
In a larger sense, the characterization of the Runx-depen-
dent CE4 silencer provides a prototype for other functionally
dedicated, developmentally specific cis-regulatory elements
that may collaborate with the URE and the promoter to shape
the complex expression pattern of PU.1. For example, we have
identified a new myeloid enhancer at kb 10.3, CE5. There is
an additional conserved cluster, CE6 and CE7, located from kb
12.5 to 12 that can mediate enhancer activity in a non-cell-
type-specific way in transient assays, but it may have more
restricted functions in a chromatin context (Zarnegar, unpub-
lished). Additional lineage-specific elements may refine PU.1
expression in other cell types. Recent evidence from others
shows that in erythroid cells GATA factors may modulate
PU.1 gene expression through binding to another conserved
site at kb 17.8, upstream of the URE (9). Although T-cell
GATA-3 should also recognize these sites, in vivo GATA-3
does not appear to bind to the 17.8 sites or promoter-asso-
ciated GATA sites in immature T cells as they silence PU.1
expression (M. Zarnegar and J. Zhang, unpublished results),
so these sites may be specific for regulation in erythroid and
megakaryocytic lineages. Thus, the complex lineage-specific
regulation of Sfpi1 is not played out simply through transcrip-
tion factor interactions at the URE and the promoter, but also
through lineage-specific intermodular interactions between the
URE and a variable set of other conserved regulatory ele-
ments.
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